Dipexium Pharmaceuticals Announces Issuance of Patent
Dipexium Pharmaceuticals, Inc. recently announced that the European Patent Office has issued a new Locilex patent in the European Union (EU). The patent claims are directed to a novel formulation of Locilex, a topical antimicrobial peptide formulated as a topical cream, and the use of Locilex as a method of treating skin or wound infections. The issued patent has an expiry date in June 2033.
“This constitutes the first patent granted by the European Union, the second largest pharmaceuticals market in the world,” stated David P. Luci, President and Chief Executive Officer of Dipexium. “This is an important building block for our commercialization strategy for Locilex in Europe. Dipexium now has issued patents for Locilex in the US, EU, and Japan, the three largest pharmaceuticals markets in the world, as well as Australia and New Zealand. In addition, Dipexium has obtained notice of allowance for patents in Hong Kong and Korea. We anticipate the issuance of additional patents for Locilex in other major international markets throughout 2016 and 2017.”
Dipexium Pharmaceuticals, Inc. is a late-stage pharmaceutical company focused on the development and commercialization of Locilex (pexiganan cream 0.8%), a novel, broad-spectrum, topical antimicrobial peptide. Initially, Locilex is targeted for the treatment of mild infections of diabetic foot ulcers. Based on a compilation of available clinical and microbiology data, Dipexium also considers Locilex to be a promising product candidate to treat other mild and moderate skin and skin structure infections, including infected decubitus ulcers, infected burns, infected surgical wounds, infected animal bites, and nasal colonization of methicillin-resistant staphylococcus aureus (MRSA). For more information, visit www.dipexiumpharmaceuticals.com.
Total Page Views: 1072
